Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Given Average Rating of “Moderate Buy” by Analysts

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) have received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $7.3333.

Several analysts recently issued reports on WHWK shares. Citizens Jmp started coverage on Whitehawk Therapeutics in a report on Thursday, April 16th. They issued a “market outperform” rating and a $8.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $7.00 target price on shares of Whitehawk Therapeutics in a research note on Friday. Citigroup began coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They set an “outperform” rating on the stock. Wall Street Zen downgraded Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Friday, March 27th.

Insider Buying and Selling at Whitehawk Therapeutics

In other Whitehawk Therapeutics news, insider Bryan Ball sold 92,460 shares of Whitehawk Therapeutics stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $3.64, for a total transaction of $336,554.40. Following the sale, the insider owned 397,106 shares of the company’s stock, valued at $1,445,465.84. The trade was a 18.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David James Lennon sold 14,500 shares of Whitehawk Therapeutics stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $3.38, for a total value of $49,010.00. Following the sale, the chief executive officer directly owned 518,622 shares in the company, valued at $1,752,942.36. The trade was a 2.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 705,358 shares of company stock valued at $2,584,564 in the last quarter. Corporate insiders own 49.90% of the company’s stock.

Institutional Trading of Whitehawk Therapeutics

Several hedge funds have recently added to or reduced their stakes in WHWK. Quadrature Capital Ltd acquired a new position in shares of Whitehawk Therapeutics during the 4th quarter valued at $28,000. ABG Innovation Capital Partners III GP Ltd acquired a new position in shares of Whitehawk Therapeutics during the 3rd quarter valued at $51,000. Dimensional Fund Advisors LP acquired a new position in shares of Whitehawk Therapeutics during the 3rd quarter valued at $84,000. Squarepoint Ops LLC acquired a new position in shares of Whitehawk Therapeutics during the 3rd quarter valued at $159,000. Finally, Marshall Wace LLP acquired a new position in shares of Whitehawk Therapeutics during the 4th quarter valued at $164,000. Institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Stock Performance

Shares of NASDAQ WHWK opened at $3.97 on Monday. The company has a market cap of $196.32 million, a price-to-earnings ratio of -2.36 and a beta of 0.70. Whitehawk Therapeutics has a 12-month low of $1.57 and a 12-month high of $4.48. The stock’s 50 day simple moving average is $3.75 and its 200 day simple moving average is $2.96.

Whitehawk Therapeutics (NASDAQ:WHWK) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.04. As a group, equities analysts forecast that Whitehawk Therapeutics will post -1.43 earnings per share for the current fiscal year.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.